Literature DB >> 21148252

CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.

Feng Li1, Jie Lu, Laiyou Wang, Xiaochao Ma.   

Abstract

Atazanavir (ATV) is an antiretroviral drug of the protease inhibitor class. Multiple adverse effects of ATV have been reported in clinical practice, such as jaundice, nausea, abdominal pain, and headache. The exact mechanisms of ATV-related adverse effects are unknown. It is generally accepted that a predominant pathway of drug-induced toxicity is through the generation of reactive metabolites. Our current study was designed to explore reactive metabolites of ATV. We used a metabolomic approach to profile ATV metabolism in mice and human liver microsomes. We identified 5 known and 13 novel ATV metabolites. Three potential reactive metabolites were detected and characterized for the first time: one aromatic aldehyde, one α-hydroxyaldehyde, and one hydrazine. These potential reactive metabolites were primarily generated by CYP3A. Our results provide a clue for studies on ATV-related adverse effects from the aspect of metabolic activation. Further studies are suggested to illustrate the impact of these potential reactive metabolites on ATV-related adverse effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148252      PMCID: PMC3061559          DOI: 10.1124/dmd.110.036327

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  Acute hepatic cytolysis in an HIV-infected patient taking atazanavir.

Authors:  Serge P Eholié; Karine Lacombe; Lawrence Serfaty; Dominique Wendum; Pierre-Marie Girard
Journal:  AIDS       Date:  2004-07-23       Impact factor: 4.177

Review 2.  Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?

Authors:  H Spahn-Langguth; L Z Benet
Journal:  Drug Metab Rev       Date:  1992       Impact factor: 4.518

Review 3.  Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.

Authors:  Wei Tang; Anthony Y H Lu
Journal:  Drug Metab Rev       Date:  2010-05       Impact factor: 4.518

4.  Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone).

Authors:  Chi Chen; Linghua Meng; Xiaochao Ma; Kristopher W Krausz; Yves Pommier; Jeffrey R Idle; Frank J Gonzalez
Journal:  J Pharmacol Exp Ther       Date:  2006-06-14       Impact factor: 4.030

Review 5.  Applying mechanisms of chemical toxicity to predict drug safety.

Authors:  F Peter Guengerich; James S MacDonald
Journal:  Chem Res Toxicol       Date:  2007-02-16       Impact factor: 3.739

Review 6.  Atazanavir for the treatment of human immunodeficiency virus infection.

Authors:  Anthony J Busti; Ronald G Hall; David M Margolis
Journal:  Pharmacotherapy       Date:  2004-12       Impact factor: 4.705

Review 7.  Atazanavir: new option for treatment of HIV infection.

Authors:  Diane V Havlir; Steven D O'Marro
Journal:  Clin Infect Dis       Date:  2004-05-13       Impact factor: 9.079

8.  Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor.

Authors:  R ter Heine; M J X Hillebrand; H Rosing; E C M van Gorp; J W Mulder; J H Beijnen; A D R Huitema
Journal:  Drug Metab Dispos       Date:  2009-06-22       Impact factor: 3.922

9.  Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.

Authors:  Feng Li; Laiyou Wang; Grace L Guo; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2010-01-26       Impact factor: 3.922

10.  Role of atazanavir in the treatment of HIV infection.

Authors:  Pablo Rivas; Judit Morello; Carolina Garrido; Sonia Rodríguez-Nóvoa; Vincent Soriano
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more
  12 in total

1.  Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure.

Authors:  Sarah K Himes; Yanling Huo; George K Siberry; Paige L Williams; Mabel L Rice; Patricia A Sirois; Toni Frederick; Rohan Hazra; Marilyn A Huestis
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

2.  Metabolomics of bronchoalveolar lavage differentiate healthy HIV-1-infected subjects from controls.

Authors:  Sushma K Cribbs; Youngja Park; David M Guidot; Greg S Martin; Lou Ann Brown; Jeffrey Lennox; Dean P Jones
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-10       Impact factor: 2.205

3.  PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria Alvarellos; Chantal Guillemette; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-05       Impact factor: 2.089

4.  Metabolomic screening and identification of the bioactivation pathways of ritonavir.

Authors:  Feng Li; Jie Lu; Xiaochao Ma
Journal:  Chem Res Toxicol       Date:  2011-11-17       Impact factor: 3.739

5.  A High Dose of Isoniazid Disturbs Endobiotic Homeostasis in Mouse Liver.

Authors:  Feng Li; Pengcheng Wang; Ke Liu; Mariana G Tarrago; Jie Lu; Eduardo N Chini; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2016-08-16       Impact factor: 3.922

6.  Profiling the reactive metabolites of xenobiotics using metabolomic technologies.

Authors:  Feng Li; Jie Lu; Xiaochao Ma
Journal:  Chem Res Toxicol       Date:  2011-04-21       Impact factor: 3.739

7.  CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolism.

Authors:  Feng Li; Jie Lu; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2013-11-08       Impact factor: 3.922

8.  Biotransformation of Cobicistat: Metabolic Pathways and Enzymes.

Authors:  Pengcheng Wang; Amina I Shehu; Ke Liu; Jie Lu; Xiaochao Ma
Journal:  Drug Metab Lett       Date:  2016

9.  Bedaquiline metabolism: enzymes and novel metabolites.

Authors:  Ke Liu; Feng Li; Jie Lu; Shinlan Liu; Kenneth Dorko; Wen Xie; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2014-02-10       Impact factor: 3.922

10.  A novel humanized mouse lacking murine P450 oxidoreductase for studying human drug metabolism.

Authors:  Mercedes Barzi; Francis P Pankowicz; Barry Zorman; Xing Liu; Xavier Legras; Diane Yang; Malgorzata Borowiak; Beatrice Bissig-Choisat; Pavel Sumazin; Feng Li; Karl-Dimiter Bissig
Journal:  Nat Commun       Date:  2017-06-28       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.